Image
Figure Caption

Fig. 4 Sunitinib malate significantly improves visual function and reduces VEGF expression in vhl−/− larvae. A) Gross morphology of sibling and vhl-/- larvae treated with increasing doses of sunitinib malate at 5 dpf. Treatment reduces yolk and cardiac oedema but does not result in swim bladder inflation. B) All concentrations of sunitinib tested increase OKR visual function at 5 dpf with 1 μM sunitinib malate highlighting a statistically significant improvement. n = 3, 12 technical replicates per experiment. C) Correlation between hyaloid vessel number and visual function in 5 dpf wildtype larvae treated with sunitinib malate. n = 3 with 10 technical replicates per experiment. Dotted line denotes vhl−/− visual function and number of primary hyaloid branches at 5 dpf. D) VMR Max ‘ON’ response is significantly increased dose dependently in larvae treated with 0.2 μM and 0.5 μM Sunitinib. n = 3, 12 technical replicates per treatment group per experiment. E) VMR chromatograms illustrating the average Max ON and Max OFF peaks after treatment. F) Expression of pro- and anti-angiogenic vhl−/− larval eyes following sunitinib treatment.

Figure Data
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.

Reprinted from Developmental Biology, 457(2), Ward, R., Ali, Z., Slater, K., Reynolds, A.L., Jensen, L.D., Kennedy, B.N., Pharmacological restoration of visual function in a zebrafish model of von-Hippel Lindau disease, 226-234, Copyright (2019) with permission from Elsevier. Full text @ Dev. Biol.